Business

Roche pays $510 million for rights to Chinese cancer-drug portfolio

Roche has agreed to pay $510 million for rights to a portfolio of antibody-drug conjugates developed by China’s Hansoh Pharma. Hansoh will lead early development, with Roche set to take over global development after the first clinical phase, subject to regional exceptions.